Abstract Body

Background: Lymphogranuloma venereum (LGV), caused by lymphotropic invasive strains of Chlamydia trachomatis (L1-L3 serovars), is a sexually transmitted infection characterised by severe inflammation, often with systemic symptoms. The clinical course of LGV can be divided into three stages. The primary stage, often unnoticed by the patient, consists of a small painless papule which may ulcerate. The secondary stage occurs a few weeks later and may manifest as either regional bubo formation or as the anorectal syndrome with haemorrhagic proctocolitis. The latter typically occurs in men-whohave- sex-with-men (MSM) or women practicing receptive anal intercourse. If left untreated, LGV may result in the tertiary stage characterized by extensive fibrosis of tissue, strictures and genital elephantiasis. LGV is endemic in parts of Africa, Asia, South America and the Caribbean. More recently, LGV has reemerged among MSM in Europe and North America. Molecular typing has demonstrated that the majority of the European LGV-associated C. trachomatis strains are clonal (serovar L2b), whilst the North American strains are more diverse. Accordingly, it has been hypothesized that the L2b variant was recently imported into Europe from North America. Anorectal LGV in MSM has been strongly associated with HIV seropositivity. This observation may be explained by serosorting, increased biological susceptibility to LGV infection, epidemiological synergy wih LGV leading to increased HIV acquisition and, possibly, the effects of the immune restoration inflammatory syndrome associated with the commencement of antiretrovial therapy. Diagnosis of LGV has traditionally relied upon serological techniques; these are only really useful for diagnosing LGV from the secondary stage onwards. Following the re-emergence of LGV in the northern hemisphere, a number of in-house nucleic acid amplification tests (NAATs) have been developed which can diagnose LGV infections from the primary stage onwards. In those situations where LGV-specific NAATs are unavailable, treatment for LGV is recommended in cases of proven anorectal chlamydial infection in MSM patients when proctitis is visualized by proctoscopy, white cells are detected at levels >10 cells per high power field in anorectal smears and when the patient is known to be HIV-infected. LGV is best treated with a 3-weeks’ course of doxycyline (100 mg 12-hourly) or, alternatively, with a 3-weeks’ course of erythromycin (500 mg 6-hourly). Conclusions: LGV has re-emerged as an important STI among HIV-infected MSM. Clinicians should consider LGV as a differential diagnosis for proctocolitis and genital ulceration in this patient group. Where possible, LGV-specific NAATs should confirm a presumptive LGV diagnosis.